Study: NCT06213506

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.